Finch Therapeutics Group, Inc. (FNCH)
|Net Income (ttm)||-39.34M|
|Trading Day||April 9|
|Day's Range||16.67 - 17.97|
|52-Week Range||15.26 - 22.50|
Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...
SOMERVILLE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...
Finch Therapeutics Group, a Phase 3-ready biotech developing microbiome therapeutics, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Finch Therapeutics Group, Inc. has filed to go public with an IPO on the NASDAQ.
Finch Therapeutics Group is a clinical-stage microbiome therapeutics company leveraging our Human-First Discovery platform to develop a novel class of orally administered biological drugs. The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to our health. When key microbes are lost, the resulting dysbiosis can increase susceptibility to immune disorders, infections, neurological conditions, cancer and other serious diseases. We are developing novel therapeutics designed to deliver mis... [Read more...]
|IPO Date |
Mar 19, 2021
Mark Smith, Ph.D.
|Stock Exchange |
|Ticker Symbol |
In 2020, FNCH's revenue was $7.72 million, a decrease of -23.98% compared to the previous year's $10.15 million. Losses were -$39.34 million, 89.6% more than in 2019.